Search research articles
Contact Us
Filters
Showing results (81-90 of 1,833) with videos related to
Page
of 184
Sort By:
Mabs
|
February 22, 2022
Improved therapeutic index of an acidic pH-selective antibody
Peter S Lee, Katherine G MacDonald, Evan Massi, et al.
Mabs
|
March 14, 2022
Computational models for studying physical instabilities in high concentration biotherapeutic formulations
Marco A Blanco
Mabs
|
April 7, 2022
Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model
Peng Zhao, Yasuaki Anami, Peng Gao, et al.
Mabs
|
April 5, 2022
Upstream cell culture process characterization and in-process control strategy development at pandemic speed
Jianlin Xu, Jianfa Ou, Kyle P McHugh, et al.
Mabs
|
October 9, 2018
Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab
Nayoung Lee, JongAh Joanne Lee, Hahymn Yang, et al.
Mabs
|
October 9, 2018
Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry
Florian Füssl, Anne Trappe, Ken Cook, et al.
Mabs
|
March 24, 2022
Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales
Sara Rodriguez-Conde, Sophie Inman, Viv Lindo, et al.
Mabs
|
June 19, 2018
Corrigendum
Mabs
|
April 28, 2010
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Frank R Brennan, Laura Dill Morton, Sebastian Spindeldreher, et al.
Mabs
|
April 27, 2010
Structural and functional characterization of the trifunctional antibody catumaxomab
Dirk Chelius, Peter Ruf, Patrick Gruber, et al.
Page
of 184
Search research articles
Search
Showing results (81-90 of 1,833) with videos related to
Sort By:
Page
of 184
Mabs
|
February 22, 2022
Improved therapeutic index of an acidic pH-selective antibody
Peter S Lee, Katherine G MacDonald, Evan Massi, et al.
Mabs
|
March 14, 2022
Computational models for studying physical instabilities in high concentration biotherapeutic formulations
Marco A Blanco
Mabs
|
April 7, 2022
Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model
Peng Zhao, Yasuaki Anami, Peng Gao, et al.
Mabs
|
April 5, 2022
Upstream cell culture process characterization and in-process control strategy development at pandemic speed
Jianlin Xu, Jianfa Ou, Kyle P McHugh, et al.
Mabs
|
October 9, 2018
Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab
Nayoung Lee, JongAh Joanne Lee, Hahymn Yang, et al.
Mabs
|
October 9, 2018
Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry
Florian Füssl, Anne Trappe, Ken Cook, et al.
Mabs
|
March 24, 2022
Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales
Sara Rodriguez-Conde, Sophie Inman, Viv Lindo, et al.
Mabs
|
June 19, 2018
Corrigendum
Mabs
|
April 28, 2010
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Frank R Brennan, Laura Dill Morton, Sebastian Spindeldreher, et al.
Mabs
|
April 27, 2010
Structural and functional characterization of the trifunctional antibody catumaxomab
Dirk Chelius, Peter Ruf, Patrick Gruber, et al.
Page
of 184